USPTO serial 98424308
THI OBI
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Mar 24, 2026
- Examiner
- OSBORNE, AUDRIANA R
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with THI OBI?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Taipei City, TW
Taipei City, TW
Taipei City, TW
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Ran He
10190 HARWIN DR. STE B,HOUSTON, TX 77036United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Carbide; Cellulose; Glycogen; Glycoprotein; Sulfides; Active chemical ingredients for use in the manufacture of anti-cancer drugs; Adjuvants, other than for medical or veterinary purposes; Antioxidants for use in the manufacture of pharmaceuticals; Biochemical catalysts; Biological preparations for use in industry and science; Carbonic hydrates; Chemical additives for use in the manufacture of pharmaceuticals; Chemical preparations for scientific purposes, other than for medical or veterinary use; Chemical substances for analyses in laboratories, other than for medical or veterinary purposes; Fatty acids for use in pharmaceutical; Polymers and polymeric additives for use in the manufacture of pharmaceutical preparations, plastics, cosmetics, personal care products, coatings, adhesives, and lubricants; Protein in raw material form for scientific and medical research; Proteins for use in manufacture; Proteins for use in the manufacture of drugs | ACTIVE | — |
| 005 | Immunostimulants; Vaccines; Adjuvants for medical purposes; Anti-cancer preparations; Biological preparations for the treatment of cancer; Chemical preparations for pharmaceutical or medical purposes, namely, for cancer to be prevented or treated; Chemical reagents for medical or veterinary purposes; Enzyme preparations for medical purposes; Enzymes for medical purposes; Ferments for pharmaceutical purposes; Hormones for medical purposes; Medicinal preparations for the treatment of infectious diseases and for use in oncology; Pharmaceutical preparations for suppressing tumors; Pharmaceutical preparations for the treatment and prevention of cancer; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of cancer; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Preparations of microorganisms for medical purposes; Tumor suppressing agents | ACTIVE | — |
| 042 | Biological research; Biological research and analysis; Chemical analysis; Chemical research; Chemical research and analysis; Chemical research services; Medical and scientific research in the field of cancer treatment and diagnosis; Medical research; Medical research in the field of oncology; Medical research services; Medical research services in the field of cancer; Pharmaceutical research and development; Providing information about medical research in the field of cancer, oncology; Providing laboratory research services in the field of gene expression, namely, cancer biology; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Scientific laboratory services; Scientific research; Scientific research and development; Scientific research in the field of genetics; Technical research in the field of pharmaceutical studies | ACTIVE | — |
| 044 | Administering vaccines to patients; Alternative medicine services; Cancer screening services; Cultured cell bank services for medical transplantation; Health care; Health care services for treating cancer; Health assessment services; Health counselling; Human tissue bank services; Medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Medical assistance; Medical screening; Medical treatment using cultured cells; Nursing, medical; Occupational therapy; Providing health information in the field of cancer prevention and treatment; Providing information in the field of cancer prevention, screening, diagnosis and treatment; Regenerative medicine services; Remote monitoring of medical data for medical diagnosis and treatment; Telemedicine services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by OBI PHARMA, INC.
- Other trademarks owned by OBI PHARMA, INC.
- Other trademarks owned by OBI PHARMA, INC.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named THI OBI
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 24, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Mar 24, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 3, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 3, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 28, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 27, 2025 | OTHE | CASE RETURNED TO EXAMINATION | — |
| Oct 27, 2025 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Oct 27, 2025 | PCBG | PETITION TO DIRECTOR - CHANGE BASIS - GRANTED | — |
| Oct 22, 2025 | APET | ASSIGNED TO PETITION STAFF | — |
| Sep 22, 2025 | TPAD | TEAS PETITION TO AMEND BASIS RECEIVED | — |
| Mar 3, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 17, 2024 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Dec 16, 2024 | EXT1 | SOU EXTENSION 1 FILED | — |
| Dec 16, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 1, 2024 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Aug 6, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 6, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 17, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 27, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 27, 2024 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jun 27, 2024 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jun 27, 2024 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jun 27, 2024 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jun 26, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 4, 2024 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Apr 3, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 1, 2024 | NWAP | NEW APPLICATION ENTERED | — |